Esperion Acquires Corstasis, Bolsters Cardiovascular Portfolio with Nasal Diuretic
Event summary
- Esperion Therapeutics completed its acquisition of privately-held Corstasis Therapeutics on April 2, 2026.
- The acquisition brings Enbumyst, the first FDA-approved nasal spray loop diuretic, into Esperion’s cardiovascular franchise.
- Enbumyst received FDA approval in September 2025 for edema treatment associated with congestive heart failure, hepatic, and renal disease.
- Esperion intends to leverage its existing cardiovascular commercial infrastructure to drive Enbumyst adoption.
The big picture
Esperion’s acquisition of Corstasis represents a strategic move to expand its presence in the cardiometabolic space, a market facing increasing global burden. The acquisition of Enbumyst, a novel nasal spray diuretic, provides a differentiated offering within the outpatient setting, but its success hinges on effective commercialization and payer acceptance. This acquisition underscores the ongoing trend of biopharma companies seeking to bolster their portfolios with innovative, patient-centric therapies.
What we're watching
- Commercial Execution
- Esperion's ability to integrate Corstasis's commercial operations and effectively leverage its existing infrastructure will be critical to Enbumyst's success and will dictate the pace of revenue generation.
- Payer Adoption
- Given Enbumyst's novel delivery method, securing favorable reimbursement and formulary placement from payers will be essential for broad patient access and market penetration.
- Competitive Landscape
- The emergence of a category-first product may attract competitors seeking to develop alternative, convenient diuretic therapies, potentially eroding Esperion's market share over time.
Related topics